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Abstract 
Purpose: Bone morphogenetic proteins (BMPs), belonging to the transforming growth factor- 
superfamily, are important regulators of cell growth, differentiation, and apoptosis.  The 
biological effects of BMPs on malignant lymphoma, however, remain unknown.  Promoter 
methylation of the BMP-6 gene in lymphomas was investigated.   
Experimental Design: We investigated BMP-6 promoter methylation and its gene expression 
in various histological types of 90 primary lymphomas and 30 lymphoma cell lines.  The impact 
of BMP-6 promoter hypermethylation on clinical outcome was also evaluated.   
Results: BMP-6 was epigenetically inactivated in subsets of lymphomas.  The silencing 
occurred with high frequency in diffuse large B-cell lymphoma (DLBCL) and Burkitt 
lymphoma (BL) in association with aberrant BMP-6 promoter methylation.  The methylation 
was observed in 60% (21/35) of DLBCL cases and 100% (7/7) of DLBCL cell lines, and in 
83% (5/6) of BL cases and 86% (12/14) of BL cell lines.  In contrast, other histological types of 
primary lymphomas studied had little or no detectable methylation (1/49; 2%).  The presence of 
BMP-6 promoter hypermethylation in DLBCL statistically correlated with a decrease in 
disease-free survival (P = 0.014) and overall survival (P = 0.038).  Multivariate analysis 
showed that the methylation profile was an independent prognostic factor in predicting 
disease-free survival (P = 0.022) and overall survival (P = 0. 046).   
Conclusion: BMP-6 promoter was hypermethylated more often in aggressive types of 
lymphomas, and the hypermethyaltion is likely to be related to the histological type of 
lymphomas.  BMP-6 promoter methylation may be a potential new biomarker of risk prediction 
in DLBCL. 
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Epigenetic gene silencing represents an important mechanism of inhibition of tumor suppressor 
gene expression in various cancers (1, 2).  In contrast to the DNA mutation that alters 
gene-encoding sequences, the epigenetic silencing affects primarily gene promoter.  Aberrant 
methylation of the promoter DNA regions rich in CpG island is the key step in the epigenetic 
gene silencing.  In malignant lymphoma, such methylation-dependent gene silencing has been 
described for a number of genes including the cyclin-dependent kinase inhibitors CDKN2A, 
CDKN2B, and KIP2, the TP53 homologue TP73, the death-associated protein kinase DAPK, 
the cellular retinol-binding protein 1 CRBP1, and other genes with putative tumor suppressor 
functions, many of which encode proteins with critical functions in cell growth control and 
apoptosis (3, 4).  Finding of additional genes whose expressions are regulated by methylation in 
malignant lymphomas will identify further genes having important roles in lymphomagenesis 
as well as prognostic implications of the diseases.   
 Malignant lymphomas constitute heterogenous groups of lymphoproliferative neoplasms 
with different bilological and clinical features.  Detailed biological mechanisms leading to the 
development of lymphomas have not been well delineated.  There have been several reports 
suggesting a potential role of transforming growth factor- (TGF-) in the pathogenesis of 
B-cell lymphoproliferative disorders (5-8).  The TGF- signaling regulates tumorigenesis and 
its pathways are often modified during tumor initiation and progression.  There is abundant 
evidence to show that TGF- acts as a negative regulator of various types of cancers and 
induces apoptosis (9-11). 
 Bone morphogenetic proteins (BMPs), belonging to the members of the TGF- superfamily, 
were originally identified as molecules that induce bone and cartilage formations, and are now 
considered multifunctional cytokines (12).  To date, over 20 BMPs have been characterized.  
Based on amino-acid homology, they can be subdivided into several different classes such as 
the BMP-2/4 group and the OP-1 group including BMP-5, -6, -7, and -8.  In various human 
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malignacies, as with TGF-, BMPs modulate cell differentiation and proliferation frequently in 
an inhibitory manner, and are thought to be involved in tumorigenesis.  For example, loss of 
BMP-2 expression has been reported in cancers of the prostate, colon and stomach (13-15), and 
inactivation of BMP-3b and BMP-6 has been suggested to promote development of lung cancer 
(16-18).  However, despite the loss of BMPs expression in these cancers, the underlying 
mechanism has not been well defined.   
 There has been a lack of unambiguous data in the literature on the specific roles of BMPs in 
the pathogenesis of malignant lymphoma.  As the promoter region of the BMP-6 gene has rich 
CpG islands (19), we were interested in investigating the methylation status of the BMP-6 gene 
promoter in malignant lymphomas with various histological types.  In this study, we found 
frequent aberrant hypermethylation and the resultant loss of BMP-6 expression in certain 
lymphomas, especially in diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma 
(BL).  Prognostic relevance of the BMP-6 promoter hypermethylation was also evaluated.   
 
Materials and methods 
Patients and cell lines.  A total of 110 lymph node tissues was obtained by incisional biopsy at 
presentation from 82 patients with non-Hodgkin lymphoma (NHL), 8 patients with Hodgkin 
lymphoma (HL), and 20 patients with reactive benign lymphadenopathy.  The diagnosis of 
malignant lymphoma was made by morphology and immunohistochemical analysis according 
to the World Health Organization (WHO) classification.  The histologic type for the NHL 
samples were DLBCL (n = 35, denoted as case DL1-35), follicular lymphoma (FL; n = 19), 
mantle cell lymphoma (MCL; n = 7), BL (n = 6), peripheral T-cell lymphoma, unspecified 
(PTCL-u; n = 8), and angioimmunoblastic T-cell lymphoma (AITL; n = 7).  All 19 FL cases 
were diagnosed as low-grade FL (grade 1 or 2) according to the WHO classification, and MCL 
cases were all histologically typical MCL, not inclusive of aggressive (blastoid) variants.  
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Peripheral blood mononuclear cells (PBMCs) from 5 healthy donors were also tested for the 
presence of BMP-6 promoter methylation.  After obtaining consents for sample drawing and 
storage, they were stored at –80oC until processing.   
 The following 30 lymphoma cell lines were also examined in this study: 7 DLBCL lines 
(Pal-1, OPL-1, OPL-2, OPL-3, OPL-4, OPL-5, and OPL-7); 14 BL lines (Akata, Katata, Raji, 
Daudi, DG75, Wan, Rael, BL-16, BL-41, Salina, Mutu I, BJAB, Namalwa, and Ramos); a 
MCL line (SP-53); a HL line (HD-70); 3 primary effusion lymphoma (PEL) lines (KS-1, 
BCBL-1, and JSC-1); and 3 CD30-positive anaplastic large cell lymphoma (ALCL) lines 
(DL-40, DL-95, and DL-110) (20).  Deglis was established from a polymorphic centroblastic 
lymphoma (Kiel classification) with dual B-cell and T-cell gene rearrangements (21).   
 
Methylation analysis.  Isolated DNA was treated with sodium bisulfite, as described previously 
(22).  Aliquots of the bisulfite-treated DNA were amplified in reaction mixtures containing 67 
mM Tis-HCl (pH 8.8), 16.6 mM (NH4)2SO4, 6.7 mM MgCl2, 10 mM -mercaptoethanol, 1.25 
mM each dNTP mixture, 0.5 M of each primer, and 1U of Ex Taq Hot Start Version 
polymerase (Takara, Tokyo, Japan).  The primers were 
5’-GGGGTAAATTTTATGGTGGTT-3’ (sense primer, designated 2F) and 5’- 
ACCTACRCCCTAACTCCTA-3’ (anti-sense, designated 2R2), which gives a PCR product of 
205 base pair (bp), encompassing the BMP-6 promoter region -521 to -316 bp relative to the 
transcriptional start site.  We also used another anti-sense primer 4R2 
(5’-CCTCAATCCTTATCTCTCATA) to amplify a 387 bp-fragment corresponding to the 
region -521 to -134 bp relative to the transcriptional start site.  The PCR condition was 3 min at 
94oC followed by 35 cycles of 94oC for 40 sec, 56oC for 30 sec, and 72oC for 30 sec.  Combined 
bisulfite restriction analysis (COBRA) was carried out by overnight digestion of the PCR 
product at 60oC with a restriction enzyme BstUI (New England BioLabs, Ipswich, MA) which 
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has the recognition sequence 5’-CGCG-3’.  The resultant DNA fragments were 
electrophoresed on agarose gels and stained with ethidium bromide.  The proportion of 
methylated (M) versus unmethylated (U) product (digested versus undigested) was quantitated 
by using a densitometer, determining the density of methylation.  The % methylation was 
calculated as follows: M/(M + U) x 100 (23).   
 
Bisulfite genomic sequencing.  The 387 bp-PCR products were purified with the Gel 
Extraction kit (Bionex, Seoul, Korea), cloned into pGEM-T Easy vector (Promega, Madison, 
WI), and transformed into Escherichia coli.  Plasmid DNA from isolated clones containing the 
insert was purified using the FlexiPrep kit (GE Healthcare Bio-Sciences, Piscataway, NJ).  
Seven to eight clones for each primary lymphoma sample and cell line were sequenced with the 
pUC/M13 primer.  The DNA sequence was determined by using the BigDye Terminator Cycle 
Sequencing kit ver.1.1 (Applied Biosystems, Foster City, CA) and an ABI 3130 automated 
DNA sequencer. 
 
Reverse-transcription (RT)-PCR.  Total RNA was isolated using Trizol reagent (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions.  Before RT, a total of 1 g of RNA 
was treated with DNase I (Invitrogen) to remove any DNA contaminant.  The DNase I-treated 
RNAs were subjected to RT with ThermoScript reverse transcriptase (Invitrogen), as 
previously described (24).  The cDNAs samples (equivalent to the cDNA amount from 50 ng of 
initial total RNA) were PCR-amplified, and the products were electrophoresed on agarose gels 
followed by ethidium bromide staining and visualization under UV light for the presence of 
DNA bands of appropriate sizes.  The sequences of the primers to amplify the BMP-6 gene by 
RT-PCR were 5’-CGACAACAGAGTCGTAATCG-3’ and 
5’-GCATTCTCCATCACAGTAATTG-3’, yielding a 195-bp fragment.  As a control for RNA 
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integrity and PCR reactions, the gene encoding -actin was amplified in parallel with following 
primers: 5’-ACCTTCAACACCCCAGCCATG-3’ and 5’- GGCCATCTCTTGCTCGAAGTC 
-3’, giving a 309-bp fragment.  
 
Western blot analysis.  Proteins (corresponding to 2 x 104 cells) were subjected to SDS-PAGE 
and electrophoretically transferred onto a polyvinylidene difluoride membrane, as previously 
described (24).  The filter was incubated with a 1: 750 dilution of the BMP-6 monoclonal 
antibody (mAb), and the second-step reaction was performed by incubation of the washed filter 
with a horseradish peroxidase-conjugated rabbit anti-mouse antibody.  Reactive proteins were 
detected by incubation of the washed filter in the enhanced chemiluminescence system 
according to the manufacturer’s instructions (GE Healthcare Bio-Sciences) followed by 
exposure to an autoradiographic film.  The mAb against -actin (Sigma, St. Louis, MO) was 
used in parallel to confirm protein integrity and immunoblot reactions.  The BMP-6 mAb 
recognized a molecular mass at around 64 kDa under reduced conditions, consistent with a size 
previously reported (25).   
 
5-aza-2’-deoxycytidine (5-aza-dC) treatment.  Two lymphoma cell lines, Pal-1 and Rael, were 
incubated in RPMI 1640 medium supplemented with 10% fetal calf serum in the presence or 
absence of 3 M of the demethylating agent 5-aza-dC (Sigma) for 6 days.  The cells were split 
on day 3 with the addition of fresh drug.  After the drug treatment, cells were harvested for 
DNA and RNA extractions.   
 
Statistical analysis.  The statistical correlation between variables was analyzed by the 
two-sided Fisher’s extract test.  Disease-free and overall survival curves were estimated by the 
Kaplan-Meier method and were compared with the use of the long-rank test.  Multivariate 
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analysis was performed with Cox’s proportional-hazards regression technique to define the 
prognostic significance of selected covariates, including methylation status.  P-value of less 
than 0.05 was considered to be significant.   
 
Results 
Methylation analysis of the BMP-6 gene in primary lymphoma samples and cell lines.  
Lymph node tissues from pretreated patients with various histological types of malignant 
lymphomas as well as non-malignant lymph nodes with reactive hyperplasia were tested for the 
presence of promoter methylation of the BMP-6 gene by COBRA with PCR products amplified 
using a primer set of 2F and 2R2.  Since aberrant hypermethylation is likely to influence not 
only the number of methylated CpG but also the density of methylation, we quantitated the 
methylation density (% methylation) (23).  We analyzed the methylation status of 20 
non-malignant lymph nodes with reactive lymphadenopathy and PBMCs from 5 healthy donors, 
none of which showed detectable methylation.  Since the densitometric assay demonstrated 
that % methylatio of these control samples did not exceed 10%, a threshold level of 10% 
methylation was chosen as evidence of presence or absence of hypermethylation of the BMP-6 
promoter.  Figure 1A shows representative results of the BMP-6 promoter methylation in 
primary lymphoma samples, and Figure 1B summarizes the distribution of methylation density 
for each histological group.  The promoter methylation of the BMP-6 gene was found in 21 
(60%) of 35 DLBCL, 5 (83%) of 6 BL, and 1 (13%) of 8 PTCL-u.  The methylation was not 
detected in any samples from FL (n = 19), MCL (n = 7), AITL (n = 7), and HL (n = 8).  These 
results indicated a significant higher frequency of BMP-6 promoter methylation in DLBCL (P 
< 0.001) and BL (P < 0.001) compared with other histological types of primary lymphomas 
studied (1/49; 2%).  Unlike cell lines with the fully methylated BMP-6 gene (as stated below), 
in these clinical samples, there were always unmethylated bands on COBRA, indicating the 
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presence of normal tissues in the lymph node samples.   
 To further investigate the BMP-6 promoter methylation in malignant lymphomas, we 
subjected 30 lymphoma cell lines to COBRA.  Illustrative examples are shown in Figure 1C, 
and Table 1 summarizes the results.  The BMP-6 promoter was fully methylated in all DLBCL 
cell lines analyzed (Pal-1, OPL-1, OPL-2, OPL-3, OPL-4, OPL-5, and OPL-7).  The 
methylation was found in 12 (86%) of 14 BL lines (Akata, Katata, Raji, Daudi, DG75, Wan, 
Rael, BL-16, BL-41, Salina, Mutu I, and BJAB), 3 (100%) of 3 PEL lines (KS-1, BCBL-1, and 
JSC-1), and 2 (67%) of 3 CD30-positive ALCL lines (DL-40 and DL-95), whereas neither 
MCL line SP-53 nor HL line HD-70 had methylated BMP-6 promoter.   
 To confirm these results, we repeated COBRA with PCR products amplified with another 
primer set 2F and 4R2.  Representative results are shown in Figure 1D.  In good concordance 
with the results of COBRA using the primer set 2F and 2R2, DLBCL and BL cases showed 
promoter hypermethylayion of BMP-6, whereas other histological types of lymphomas tested 
had little or no detectable methylation.   
 
Bisulfite sequencing analysis.  To confirm the methylation at the restriction enzyme 
(BstUI)-cleavage sites along with the methylation of other neighboring CpG sites, 5 primary 
lymphoma samples including 2 DLBCL cases (DL15 and DL32), a BL case (BL1), a FL case 
(FL3), and a HL case (HL1) as well as 3 lymphoma cell lines (Pal-1, Akata, and SP-53) were 
subjected to bisulfite sequencing.  The 387 bp-PCR products were cloned into a plasmid vector, 
and seven to eight independent clones were sequenced.  As shown in Figure 2, the bisufite 
sequencing showed good concordance with COBRA.  In lymphoma cases found to be 
methylated by COBRA (DL15, DL32, and BL1), not only the CpG sites at the BstUI cleavage 
sites but also another CpG sites were partially or fully methylated (Fig. 2A), whereas the 
unmethylated samples, FL3 and HL1, showed little methylation at CpG sites of the promoter 
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region.  As expected, extensive methylation across the entire CpG islands was seen in the 
methylated cell lines of DLBCL (Pal-1) and BL (Akata) (Fig. 2B).  In contrast, the unmethylaed 
MCL line, SP-53, showed no evidence of promoter hypermethylation of BMP-6.   
 
Association of the BMP-6 promoter methylation with transcriptional gene silencing.  To 
elucidate whether the aberrrant methylation of BMP-6 is associated with loss of BMP-6 
expression, we analyzed expression of BMP-6 transcripts in primary lymphoma cells as well as 
lymphoma cell lines by RT-PCR with cycles that amplified the -actin cDNA to plateau levels.  
Representative results are shown in Figure 3A.  Primary lymphoma samples lacking the BMP-6 
promoter methylation expressed BMP-6 mRNA transcripts, whereas samples having the 
BMP-6 promoter methylation expressed little or no detectable BMP-6 mRNAs.   
 Similarly, the lymphoma cells lines that were methylated at the BMP-6 promoter (for 
example, Pal-1, OPL-5, OPL-7, Akata, Daudi, Rael, BJAB, BCBL-1, Deglis, and DL-40) did 
not show expression of the BMP-6 RNA transcripts (Fig. 3A and Table 1).  In contrast, the cell 
lines that were unmethylated such as Ramos, Namalwa, SP-53, and HD-70, expressed the 
BMP-6 transcripts.  Ramos cells, which had been described to express BMP-6 mRNA, served 
as a positive control (26).  These results indicated that the BMP-6 promoter hypermethylation 
correlated with loss of BMP-6 expression.   
 We next assessed the association between this epigenetic aberration and transcriptional 
inactivation of the BMP-6 gene at the protein levels.  Representative results are shown in Figure 
3B.  Western blot analysis showed that there was a good correlation between the BMP-6 
promoter methylation and BMP-6 protein expression.  Methylated primary DLBCL samples 
(for example, cases DL32 and DL35) did not express the BMP-6 protein, whereas the exact 
opposite occurred in the unmethylated samples (for example, cases DL13 and DL27).  
Similarly, the hypermethylated cell lines such as Pal-1, OPL-5, OPL-7, Akata, Rael, BJAB, and 
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DL-40 lacked expression of the BMP-6 protein, while unmethylated cell lines such as Ramos, 
Namalwa, DL-110, and SP-53 expressed the protein (Fig. 3B and Table 1).   
 To confirm that this loss of expression was due to the BMP-6 promoter hypermethylation, 
two cell lines Pal-1 and Rael were incubated in the presence or absence of the 5-aza-dC, and 
methylation status and BMP-6 mRNA expression were analyzed by COBRA and RT-PCR, 
respectively.  Both Pal-1 and Rael cells had extensive promoter methylation of the BMP-6 gene, 
but treatment with 5-aza-dC led to partial demethylation (Fig. 4A).  In parallel with the 
demethylation, there was re-expression of the BMP-6 transcripts (Fig. 4B), implying that the 
methylation pattern is associated with transcriptional silencing.   
 
Clinical correlates of the BMP-6 promoter methylation in DLBCL patients.  The 35 DLBCL 
were divided into two groups: those with methylated BMP-6 promoter (n = 21) and those with 
unmethylated BMP-6 promoter (n = 14).  The association between the BMP-6 promoter 
methylation and clinical characteristics at presentation were analyzed by the Fisher’s extract 
two-tail test.  The presence of BMP-6 promoter methylation was not associated with any 
difference in the age of onset, gender, clinical stage (Ann Arbor), performance status (Eastern 
Cooperative Oncology Group), serum lactate dehydrogenase levels, number of sites of 
extranodal disease, presence of B symptoms, or bone marrow involvement (Table 2).  Most 
importantly, we found that the presence of BMP-6 promoter methylation was associated with a 
statistically significant decrease in overall survival (Kaplan-Meier, P = 0.038) and disease-free 
survival (Kaplan-Meier, P = 0.014) (Fig.5).  Multivariate analysis demonstrated that the 
presence of BMP-6 promoter methylation was independent prognostic factor for predicting 
both disease-free survival and overall survival in the series (Table 3).  These observations 
suggested that the BMP-6 promoter methylation is a likely predictor of poor outcome in 
patients with DLBCL.   
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Discussion 
 BMP-6 is a member of the TGF- superfamily of signaling molecules that are important 
negative cell proliferation regulators inducing apoptosis in various types of cells including B 
lymphocytes (12, 27).  BMP-6, like the other BMP members, signals through ligation of type I 
and type II serine-threonine kinase receptors (BMPRs), which subsequently propagates the 
signal downstream by phosphorylating receptor activated-Smad proteins (Smad1, Smad5, and 
Smad8).12  These Smads then form complexes with the common mediator Smad (Smad4), and 
are translocated into nucleus where they exert regulation of target genes specific for the BMP 
pathway.  Thus, BMP signaling is similar to the paradigm established by TGF- signaling.  It is 
logical, therefore, to assume that any functional impairment by genetic alterations or epigenetic 
inactivation of genes involved in the BMP/TGF- pathway may predispose to development of 
malignant diseases (9-11, 28).  In fact, several recent findings demonstrated the tumor 
suppressor function of BMPs.  First, BMP-2 inhibited the growth of cancer cells of many 
origins including cells derived from colorectal, prostatic, and gastric cancers (14, 29, 30).  
BMP-6 inhibited proliferation of prostate cancer cells by up-regulation of several 
cyclin-dependent kinase inhibitors (31).  Similarly, BMP-7 showed growth inhibitory effect on 
thyroid carcinoma cells by inducing cell cycle arrest via up-regulation of the cyclin-dependent 
kinase inhibitors (32).  These inhibitory effects of BMPs are consistent with the general 
characteristics of TGF- superfamily members.  Second, decreased expression of BMPR type 
II correlated with resistance to the growth-inhibitory effect of BMP-6 in renal cell carcinoma, 
suggesting that loss of sensitivity to BMP-6 is necessary to achieve the malignant phenotypes 
(33).  Third, loss of BMP-2 expression has been reported for several cancers, including 
prostatic, colorectal, and gastric cancers (13-15).  Furthermore, epigenetic inactivation of 
BMP-3b and BMP-6 by gene promoter hypermethylation promoted lung tumor development 
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(16-18).  Thus, molecular alterations involving in the BMP signaling cascade have been 
demonstrated to be associated with tumorigenesis and/or disease progression in several cancers.  
In the realm of hematological malignancies, several studies showed that BMPs (BMP-2, -4, -5, 
-6, and -7) inhibited proliferation and induce apoptosis of myeloma cells (34-37), but little is 
known about the biological roles of BMPs in other hematological malignancies including 
malignant lymphoma.   
 Of these BMPs, BMP-6 came into the focus of out interest since the BMP-6 promoter 
sequence was previously identified as a target for aberrant DNA methylation (19).  In this study, 
we have analyzed methylation status of the BMP-6 promoter region in primary lymphoma cells 
and lymphoma cell lines with various histological types.  We found intensive promoter 
methylation with significant high frequency in DLBCL and BL.  On the contrary, other 
histological types of lymphomas tested, including HL, FL (grade 1 or 2), MCL, PTCL-u, and 
AITL, showed little or no detectable methylation.  The BMP-6 promoter methylation was not 
observed in any of the lymph node tissues of reactive lymphadenopathy and PBMCs from 
healthy donors.  These findings suggested that the BMP-6 promoter methylation appears 
tumor-specific, and that there was a strong trend toward a higher BMP-6 hypermethylation 
frequency in subsets of aggressive NHLs such as DLBCL and BL, compared with indolent 
lymphomas.  We also demonstrated methylation-dependent loss of BMP-6 expression at 
mRNA and protein levels.  Furthermore, the transriptional repression is reversible by treatment 
with the demethyalting agent 5-aza-dC.  Thus, our findings implied a causal relationship 
between methylation of the BMP-6 promoter and transcriptional repression.  Our data are, to 
the best of our knowledge, the first demonstration of epigenetic inactivation of a BMP family 
member in malignant lymphoma.   
 Importantly, this study reports that the BMP-6 promoter hypermethylation may provide a 
novel independent marker for the prognostic assessment of survival in patients with DLBCL.  
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Because the number of samples analyzed is relatively small, larger randomized prospective 
studies are required to confirm the prognostic significance of BMP-6 promoter 
hypermethylation.   
 In summary, our study showed for the first time that promoter of the BMP-6 gene was 
methylated more often in aggressive types of NHLs such as DLBCL and BL.  The BMP-6 
promoter hypermethyaltion is likely to be related to the histological type of malignant 
lymphomas with more aggressive clinical behavior.  The study reported here also showed that 
BMP-6 promoter methylation profile seems to be an important marker in predicting the clinical 
outcome in DLBCL.  An understanding of the BMP signaling pathways in lymphoma cells will 
be valuable in elucidating the molecular mechanisms of the roles of BMPs in lymphomagenesis 
and for the establishment of novel strategies for their treatment.   
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Table 1.  BMP-6 promoter methylation status and BMP-6 expression in lymphoma cell lines 
 
 Cell line % methylation Expression 
 
 RT-PCR Western blot 
 
 DLBCL line 
 Pal-1 94 - - 
 OPL-1 91 - NT 
 OPL-2 96 - NT 
 OPL-3 97 - - 
 OPL-4 100 - NT 
 OPL-5 93 - - 
 OPL-7 98 - - 
 
 BL line 
 Akata 93 - - 
 Katata 30 - NT 
 Raji 75 - NT 
 Daudi 94 - NT 
 DG75 78 - NT 
 Wan 38 - - 
 Rael 95 - - 
 BL-16 95 - NT 
 BL-41 29 + - 
 Salina 50 - NT 
 Mutu I 97 - NT 
 BJAB 100 - - 
 Namalwa 9 + + 
 Ramos 0 + + 
 
 MCL line 
 SP-53 0 + + 
 
 HL line 
 HD-70 0 + NT 
 
 PEL line 
 KS-1 90 - - 
 BCBL-1 95 - NT 
 JSC-1 96 - NT 
 
 ALCL line  
 DL-40 97 - - 
 DL-95 97 - - 
 DL-110 5 + + 
 
Abbreviation: NT, not tested. 
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Table 2.  Clinical characteristics in relation to BMP-6 methylation status in patients with 
diffuse large B-cell lymphoma 
 
 No. of Patients (%) 
 
 Methylated Unmethylated P-value* 
 n = 21 (60%) n = 14 (40%) 
 
 Age at diagnosis (years) 
 ≦60 4 (19.0) 5 (35.7) 0.432 
 ＞60 17 (81.0) 9 (64.3) 
 Gender 
 Male 12 (57.1) 5 (35.7) 0.305 
 Female 9 (42.9) 9 (64.3) 
 Serum LDH 
 Normal 8 (38.1) 7 (50.0) 0.511 
 Elevated 13 (61.9) 7 (50.0) 
 Performance status (ECOG) 
 0. 1 16 (76.2) 9 (64.3) 0.474 
 >1 5 (23.8) 5 (35.7) 
 Clinical stage (Ann Arbor) 
 I, II 14 (66.7) 5 (35.7) 0.094 
 III, IV 7 (33.3) 9 (64.3) 
 Extranodal site 
 0, 1 17 (81.0) 12 (85.7) 0.999 
 >1 4 (19.0) 2 (14.3) 
 B symptoms 
 Absent 18 (85.7) 12 (85.7) 0.999 
 Present 3 (14.3) 2 (14.3) 
 BM involvement 
 Absent 18 (85.7) 11 (78.6) 0.665 
 Present 3 (14.3) 3 (21.4) 
 
*P-values are obtained from the two-tailed Fisher’s exact tests. 
Abbreviations: LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; 
BM, bone marrow. 
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Table 3.  Multivariate analysis for overall survival and disease-free survival in DLBCL 
 Feature P-value Hazard ratio 95% confidence interval 
  
 
 Overall survival 
 BMP-6 methylation: present 0.046 0.378 0.145-0.986 
 Age: >60 years 0.109 2.468 0.817-7.457 
 Gender: male 0.786 0.888 0.376-2.099 
 Serum LDH: increased 0.272 1.754 0.643-4.781 
 Performance status: >1 0.374 1.513 0.607-3.771 
 Clinical stage: III-IV 0.709 0.852  0.367-1.981 
 Extranodal site: >1 0.024 3.447 1.180-10.074 
 B symptom: present 0.788 1.160 0.391-3.440 
 BM involvement: present 0.800 1.150 0.388-3.407 
 
 Disease-free survival 
 BMP-6 methylation: present 0.022 0.327 0.125-0.856 
 Age:＞60 years 0.191 2.082 0.693-6.257 
 Gender: male 0.364 0.674 0.287-1.581 
 Serum LDH: increased 0.238 1.826 0.671-4.971 
 Performance status: >1 0.481 1.389 0.557-3.461 
 Clinical stage: III-IV 0.592 0.792 0.338-1.859 
 Extranodal site: >1 0.146 2.163 0.764-6.121 
 B symptom: present 0.984 1.011 0.341-2.998 
 BM involvement: present 0.940 1.043 0.352-3.092 
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Fig. 1  Representative COBRA results of the BMP-6 gene promoter.  A, COBRA results with 
PCR products amplified with 2F/2R2 primers in primary lymphoma cells, showing frequent 
aberrant methylation in DLBCL and BL samples, but none of samples from FL, MCL, and HL 
had methylated BMP-6 gene.  The PCR products (205 bp) from bisulfite-treated DNA were 
digested with BstU I.  DLBCL samples were divided into two groups: methylated and 
unmethylated samples.  Case numbers are shown on top.  Unmethylated (U) and methylated 
(M) bands were quantitated by densitometry.  % Methylation (percentage of methylated versus 
unmethylated bands) is shown below each lane.  B, Intensities of the BMP-6 promoter 
methylation in clinical samples.  110 lymph node tissues and PBMCs from 5 healthy donors 
were analyzed for the BMP-6 promoter methylation by COBRA.  The proportion of methylated 
versus unmethylated bands (as shown in Fig. 1A) was quantitated by a densitometer, and % 
methylation was calculated.  A fraction of >10% (indicated as a dot line) is considered evidence 
of methylation.  C, COBRA results (2F/2R2 PCR primers) in lymphoma cell lines.  D, COBRA 
results with PCR products (387 bp) amplified with 2F/4R2 primers, showing similar 
methylation patterns to those shown in Figure 1A.   
 
Fig. 2.  Methylation patterns of individual bisulfite-sequenced clones of the BMP-6 promoter in 
primary lymphoma cells (A) and lymphoma cell lines (B).  Genomic DNA was subjected to 
sodium bisulfite conversion, PCR amplification with 2F/4R2 primers, cloning, and cycle 
sequencing.  Seven to eight clones from each sample were bisulfite-sequenced to obtain a 
representative sampling of methylation patterns.  Schematic depiction of the CpG island in the 
BMP-6 promoter region are shown on top.  The 37 CpG sites analyzed are indicated by the 
vertical bars and numbered from left to right.  The translation start site is shown by a horizontal 
arrow.  BstUI sites are underlined.  Methylated and unmethylated cytosines are shown by 
closed and open squares, respectively.   
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Fig. 3.  Analysis of BMP-6 expression.  A, RT-PCR analysis for expression of BMP-6 mRNA in 
primary lymphoma cells (upper panel) and lymphoma cell lines (lower panel).  Lymphoma 
samples lacking BMP-6 methylation expressed BMP-6 mRNAs, whereas samples with BMP-6 
methylation expressed little or no detectable BMP-6 mRNA transcripts.  -Actin was used as a 
control for cDNA integrity and quality.  B, Western blot analysis for expression of BMP-6 
protein in primary lymphoma cells and lymphoma cell lines.  Proteins were assessed by 
SDS-PAGE followed by blotting onto membranes and detection with BMP-6 mAb.  
Lymphoma cells carrying BMP-6 promoter methylation did not express BMP-6 protein, 
whereas unmethylated cells expressed the protein.  -Actin is shown as a loading control.   
 
Fig. 4.  Demethylation of the BMP-6 promoter reverses transcriptional silencing.  A, COBRA 
for the BMP-6 promoter methylation in Pal-1 and Rael cells that were grown in the presence (+) 
or absence (-) of 5-aza-dC, showing partial demethylation in 5-aza-dC-treated cells.  % 
Methylation is shown below each lane.  U: unmethylated fragment; M: methylated fragment.  B, 
RT-PCR analysis showed methylation-dependent restoration of BMP-6 mRNA transcripts.  
-Actin was used as a control for cDNA integrity and quality.   
 
Fig. 5.  Overall survival and disease-free survival of patients with DLBCL according to BMP-6 
promoter methylation status during the follow-up period.  Overall survival (A) and disease-free 
survival (B) in patients with BMP-6 promoter methylation were significantly lower than in 
those without BMP-6 promoter methylation (P = 0.038 and P = 0.014, respectively, log-rank 
test). 





